vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $13.8M, roughly 1.9× FENNEC PHARMACEUTICALS INC.). FENNEC PHARMACEUTICALS INC. runs the higher net margin — -34.7% vs -49.7%, a 14.9% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 13.1%). Over the past eight quarters, BCB BANCORP INC's revenue compounded faster (1.8% CAGR vs -26.3%).
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BCBP vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $13.8M |
| Net Profit | $-12.0M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -18.5% |
| Net Margin | -49.7% | -34.7% |
| Revenue YoY | 13.1% | 73.8% |
| Net Profit YoY | -467.6% | -141.1% |
| EPS (diluted) | $-0.73 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $13.8M | ||
| Q3 25 | $26.5M | $12.5M | ||
| Q2 25 | $25.2M | $9.7M | ||
| Q1 25 | $23.8M | $8.8M | ||
| Q4 24 | $23.1M | $7.9M | ||
| Q3 24 | $26.2M | $7.0M | ||
| Q2 24 | $20.4M | $7.3M | ||
| Q1 24 | $25.3M | $25.4M |
| Q4 25 | $-12.0M | $-4.8M | ||
| Q3 25 | $4.3M | $-638.0K | ||
| Q2 25 | $3.6M | $-3.2M | ||
| Q1 25 | $-8.3M | $-1.2M | ||
| Q4 24 | $3.3M | $-2.0M | ||
| Q3 24 | $6.7M | $-5.7M | ||
| Q2 24 | $2.8M | $-5.6M | ||
| Q1 24 | $5.9M | $12.8M |
| Q4 25 | -71.9% | -18.5% | ||
| Q3 25 | 21.9% | -1.5% | ||
| Q2 25 | 19.9% | -28.3% | ||
| Q1 25 | -49.2% | -9.2% | ||
| Q4 24 | 19.9% | -11.8% | ||
| Q3 24 | 35.7% | -74.6% | ||
| Q2 24 | 19.5% | -69.4% | ||
| Q1 24 | 33.0% | 54.2% |
| Q4 25 | -49.7% | -34.7% | ||
| Q3 25 | 16.1% | -5.1% | ||
| Q2 25 | 14.2% | -32.7% | ||
| Q1 25 | -35.0% | -13.3% | ||
| Q4 24 | 14.1% | -25.0% | ||
| Q3 24 | 25.5% | -82.2% | ||
| Q2 24 | 13.8% | -76.5% | ||
| Q1 24 | 23.2% | 50.6% |
| Q4 25 | $-0.73 | $-0.17 | ||
| Q3 25 | $0.22 | $-0.02 | ||
| Q2 25 | $0.18 | $-0.11 | ||
| Q1 25 | $-0.51 | $-0.04 | ||
| Q4 24 | $0.17 | $-0.02 | ||
| Q3 24 | $0.36 | $-0.21 | ||
| Q2 24 | $0.14 | $-0.20 | ||
| Q1 24 | $0.32 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $35.5M |
| Total Assets | $3.3B | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $36.8M | ||
| Q3 25 | — | $21.9M | ||
| Q2 25 | — | $18.7M | ||
| Q1 25 | — | $22.7M | ||
| Q4 24 | — | $26.6M | ||
| Q3 24 | — | $40.3M | ||
| Q2 24 | — | $43.1M | ||
| Q1 24 | — | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $304.3M | $35.5M | ||
| Q3 25 | $318.5M | $-4.5M | ||
| Q2 25 | $315.7M | $-7.5M | ||
| Q1 25 | $314.7M | $-5.9M | ||
| Q4 24 | $323.9M | $-5.9M | ||
| Q3 24 | $328.1M | $-5.2M | ||
| Q2 24 | $320.7M | $-1.4M | ||
| Q1 24 | $320.1M | $3.0M |
| Q4 25 | $3.3B | $70.6M | ||
| Q3 25 | $3.4B | $49.3M | ||
| Q2 25 | $3.4B | $44.9M | ||
| Q1 25 | $3.5B | $46.4M | ||
| Q4 24 | $3.6B | $44.9M | ||
| Q3 24 | $3.6B | $58.9M | ||
| Q2 24 | $3.8B | $63.2M | ||
| Q1 24 | $3.8B | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-6.0M |
| Free Cash FlowOCF − Capex | $34.9M | — |
| FCF MarginFCF / Revenue | 133.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-6.0M | ||
| Q3 25 | $8.7M | $1.5M | ||
| Q2 25 | $10.3M | $-3.7M | ||
| Q1 25 | $5.0M | $-4.3M | ||
| Q4 24 | $67.7M | $-1.5M | ||
| Q3 24 | $43.5M | $-2.2M | ||
| Q2 24 | $8.1M | $-8.4M | ||
| Q1 24 | $8.3M | $39.0M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $66.5M | — | ||
| Q3 24 | $43.4M | — | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.1M | — |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 287.5% | — | ||
| Q3 24 | 166.0% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
